Improvement of hematopoietic stem cell transplantation in the targeted therapy era

Xi ZHANG; Ruihao HUANG

doi:10.16016/j.1000-5404.202108154

您当前的位置：

首页 >

文章列表页 >

Improvement of hematopoietic stem cell transplantation in the targeted therapy era

Monographic Reports: Basic and clinical research on complications after hematopoietic stem cell transplantation | 更新时间：2026-01-09

- Improvement of hematopoietic stem cell transplantation in the targeted therapy era
- Journal of Third Military Medical University Vol. 43, Issue 21, Pages: 2271-2275(2021)
- 作者机构：
  
  400037 重庆，陆军军医大学(第三军医大学)第二附属医院血液病医学中心，全军血液病中心，创伤、烧伤与复合伤国家重点实验室
- 作者简介：
- 基金信息：
  
  the (Regional) Cooperation and Exchange Project for National Natural Science Foundation of China(82020108004);the 2020 Open Project of National Clinical Medicine Research Center for Hematological System Diseases(2020ZKZC02)
- DOI：10.16016/j.1000-5404.202108154
  CLC： R617;R733.7
- Received：23 August 2021，
  
  Revised：2021-09-28，
  
  Published：15 November 2021
- 稿件说明：
移动端阅览
Xi ZHANG, Ruihao HUANG. Improvement of hematopoietic stem cell transplantation in the targeted therapy era[J]. Journal of Third Military Medical University, 2021, 43(21): 2271-2275.
DOI：

Xi ZHANG, Ruihao HUANG. Improvement of hematopoietic stem cell transplantation in the targeted therapy era[J]. Journal of Third Military Medical University, 2021, 43(21): 2271-2275. DOI： 10.16016/j.1000-5404.202108154.

摘要

造血干细胞移植是治愈血液肿瘤的手段之一，异基因造血干细胞移植技术在我国发展迅速，形成了许多具有中国特色的移植方案和技术体系，尤其是单倍型造血干细胞移植的成熟运用，基本解决了供者来源受限的问题。表观遗传调控药物、靶向白血病关键通路及免疫细胞疗法的不断涌现，为血液肿瘤治疗提供了新选择，也为造血干细胞移植提供了新的赋能手段。本文对新药在异基因造血干细胞移植全程(移植前、中、后)的应用及相关临床新技术、新方案进行总结，认为靶向药物等新药与造血干细胞移植更加紧密地联合是进一步提高移植疗效、增加安全性的有效方法；将现有的造血干细胞移植技术与新药有机地整合出最佳方案，以进一步提升疗效并提高患者生存质量，是今后该领域研究须重点关注的问题。

Abstract

Hematopoietic stem cell transplantation (HSCT) is one of best ways to treat hematological malignancies. And

allogeneic HSCT has been developing rapidly in our country within recent decades

and accomplished many transplantation schemes and technological systems with Chinese characteristics. Especially

the mature application of haplo-identical HSCT promotes the transplantation into an era of "everyone has a donor". Nowadays

constantly emerged epigenetic regulators

pathway modulators of leukemia genesis and immune cell therapies have provided more options for physician and patients so far in HSCT. In this article

we summarize the application of new drugs in the whole process of allogeneic HSCT (before

during and after transplantation) and related new technologies and new schemes. We consider that the closer combination of new drugs such as targeted drugs and HSCT is an effective measure to further improve the efficacy and safety of allogeneic HSCT. We should organically integrate the existing technologies and new drugs into the best scheme in order to further enhance the efficacy and improve the quality of life of patients. This is a problem that must be focused on in this field in the future.

关键词

Keywords

references

SUGITA J. HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide[J]. Int J Hematol, 2019, 110(1): 30-38. DOI: 10.1007/s12185-019-02660-8.

GAGELMANN N, BACIGALUPO A, RAMBALDI A, et al . Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: a systematic review and meta-analysis[J ] . JAMA Oncol, 2019, 5(12): 1739-1748. DOI: 10.1001/jamaoncol.2019.3541..

HUANG R, LI X, HE Y, et al . Recent advances in CAR-T cell engineering[J ] . J Hematol Oncol, 2020, 13(1): 86. DOI: 10.1186/s13045-020-00910-5.

CORTES J, KANTARJIAN H. Chronic myeloid leukemia: sequencing of TKI therapies[J]. Hematology, 2016, 2016(1): 164-169. DOI: 10.1182/asheducation-2016.1.164.

CZYZ A, NAGLER A. The role of measurable residual disease (MRD) in hematopoietic stem cell transplantation for hematological malignancies focusing on acute leukemia[J]. Int J Mol Sci, 2019, 20(21): 5362. DOI: 10.3390/ijms20215362.

PARK J H, RIVIÈRE I, GONEN M, et al . Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia[J ] . N Engl J Med, 2018, 378(5): 449-459. DOI: 10.1056/nejmoa1709919.

WEN S, NIU Z, XING L, et al . CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report[J ] . BMC Cancer, 2018, 18(1): 1143. DOI: 10.1186/s12885-018-5037-7.

GOEBELER M E, BARGOU R C. T cell-engaging therapies-BiTEs and beyond[J]. Nat Rev Clin Oncol, 2020, 17(7): 418-434. DOI: 10.1038/s41571-020-0347-5.

FLOTHO C, SOMMER S, LVBBERT M. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia[J]. Semin Cancer Biol, 2018, 51: 68-79. DOI: 10.1016/j.semcancer.2017.10.011.

郑慧菲, 王婧, 周进, 等. 地西他滨桥接异基因造血干细胞移植治疗骨髓增生异常综合征的疗效分析[J]. 中华血液学杂志, 2015, 36 (2): 121-124. DOI: 10.3760/cma.j.issn.0253-2727.2015.02.008.

ZHENG H F, WANG J, ZHOU J, et al . Retrospective efficacy analysis of decitabine bridging allogeneic hematopoietic stem cell transplantation on the treatment of myelodysplastic syndrome[J ] . Chin J Hematol, 2015, 36(2): 121-124. DOI: 10.3760/cma.j.issn.0253-2727.2015.02.008.

HUI Y, LI Y, TONG X W, et al . Reinduction chemotherapy regimen involved decitabine and cladribine improves the prognosis of patients with relapsed or refractory acute myeloid leukemia: a preliminary study[J ] . Int J Cancer, 2021: ijc. 33595. DOI: 10.1002/ijc.33595.

SPIERINGS E, KIM Y H, HENDRIKS M, et al . Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation[J ] . Biol Blood Marrow Transplant, 2013, 19(8): 1244-1253. DOI: 10.1016/j.bbmt.2013.06.001.

CAO Y G, HE Y, ZHANG S D, et al . Conditioning regimen of 5-day decitabine administration for allogeneic stem cell transplantation in patients with myelodysplastic syndrome and myeloproliferative neoplasms[J ] . Biol Blood Marrow Transplant, 2020, 26(2): 285-291. . DOI: 10.1016/j.bbmt.2019.09.001

TANG X W, VALDEZ B C, MA Y J, et al . Low-dose decita bine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation[J ] . Bone Marrow Transplant, 2021, 56(7): 1674-1682. DOI: 10.1038/s41409-021-01238-5.

ZHANG C, CHEN X H, LIU J, et al . Decitabine as a conditioning regimen in haploidentical stem cell transplantation for refractory acute myeloid leukaemia[J ] . J Clin Pharm Ther, 2015, 40(3): 336-338. DOI: 10.1111/jcpt.12251.

SERVAIS S, BARON F, BEGUIN Y. Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning[J]. Transfus Apher Sci, 2011, 44(2): 205-210. DOI: 10.1016/j.transci.2011.01.019.

SANDMAIER B M, KORNBLIT B, STORER B E, et al . Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial[J ] . Lancet Haematol, 2019, 6(8): e409-e418. DOI: 10.1016/S2352-3026(19)30088-2.

LI M M, LI C, GENG S X, et al . Decitabine with or without micro-transplantation for the treatment of intermediate or high-risk myelodysplastic syndrome: a Chinese single-center retrospective study of 22 pati ents[J ] . Front Oncol, 2021, 11: 628127. DOI: 10.3389/fonc.2021.628127.

ZHANG C, KONG P Y, LI S Q, et al . Donor-derived CAR-T cells serve as a reduced-intensity conditioning regimen for haploidentical stem cell transplantation in treatment of relapsed/refractory acute lymphoblastic leukemia: case report and review of the literature[J ] . J Immunother, 2018, 41(6): 306-311. DOI: 10.1097/cji.0000000000000233.

CHANG Y J, WU D P, LAI Y R, et al . Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study[J ] . J Clin Oncol, 2020, 38(29): 3367-3376. DOI: 10.1200/jco.20.00150.

MO X D, XU L P, ZHANG X H, et al . Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome[J ] . Bone Marrow Transplant, 2015, 50(1): 127-133. DOI: 10.1038/bmt.2014.223.

MA Y J, QU C J, DAI H P, et al . Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia[J ] . Bone Marrow Transplant, 2020, 55(6): 1206-1208. DOI: 10.1038/s41409-019-0677-z.

GAO L, ZHANG Y Q, WANG S B, et al . Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial[J ] . J Clin Oncol, 2020, 38(36): 4249-4259. DOI: 10.1200/jco.19.03277.

XUAN L, WANG Y, HUANG F, et al . Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial[J ] . Lancet Oncol, 2020, 21(9): 1201-1212. DOI: 10.1016/S1470-2045(20)30455-1.

SAINI N, MARIN D, LEDESMA C, et al . Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL[J ] . Blood, 2020, 136(15): 1786-1789. DOI: 10.1182/blood.2019004685.

ZHANG C, WANG X Q, ZHANG R L, et al . Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant[J ] . Leukemia, 2021, 35(6): 1563-1570. DOI: 10.1038/s41375-020-01056-6.

GAO L, ZHANG Y Q, HU B Y, et al . Phase Ⅱ multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation[J ] . J Clin Oncol, 2016, 34(24): 2843-2850.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Emerging advances in clinical diagnosis and treatment of hepatocellular carcinoma: evolution of comprehensive treatment strategies

Efficacy and safety of immunotherapy combined with targeted therapy and chemotherapy in third-line treatment of microsatellite stable metastatic colorectal cancer

Iron chelation therapy improves hematopoiesis in patients with hematological malignancy after hematopoietic stem cell transplantation

Related Author

LI Jianwei

WANG Xingru

ZHAO Wensi

SONG Jian

Cong ZENG

Xu CHEN

Juan HUA

Tingting CHENG

Related Institution

Institute of Hepatobiliary Surgery of PLA，First Affiliated Hospital， Army Medical University （Third Military Medical University）

No.953，Xigaze， Tibet Autonomous Region

Department of Pharmacy, Renmin Hospital of Wuhan University

Department of Oncology, Renmin Hospital of Wuhan University

Department of Hematology, Xiangya Hospital, Central South University

⁰